http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
3형제에서 발현된 Caroli병을 동반한 선천성 간 섬유화증 3예
이인철 ( In Chul Lee ),이영상 ( Young Sang Lee ),김명환 ( Myung Hwan Kim ),유은실 ( Eun Sil Yu ),민영일 ( Young Il Min ),류진숙 ( Jin Sook Ryu ),김해련 ( Hae Ryun Kim ),정영화 ( Young Hwa Joung ) 대한소화기학회 1990 대한소화기학회지 Vol.22 No.2
We have experienced 3 cases of congenital hepatic fibrosis with Caroli's disease in 3 siblings, whose clinical manifestations were diverse such as repeated cholangitis or variceal hemorrhage. They also had multiple renal cysts, so we suppose that the clinical entities of these patients are in the spectrum of fibropolycystic disease of liver and kidney.
담도 및 췌장 악성종양에서의 CA19-9의 진단적 가치에 대한 평가
명승재(Sung Jae Myung),최승목(Sung Mok Choi),김은옥(Eun Ok Kim),최호순(Ho Soon Choi),이성구(Sung Koo Lee),김명환(Myung Hwan Kim),민영일(Young Il Min),류진숙(Jin Sook Ryu) 대한소화기학회 1995 대한소화기학회지 Vol.27 No.3
N/A Background/Aims: The CA19-9 is a tumor marker used for gastrointestinal tumors, especially pancreatic cancer and biliary tract malignancy. However, it was also reported that there are some CA19-9 positive parients with benign diseases. The aim of this study is to evaluate the diagnostic value of CA19-9 in malignant and benign pancreaticobiliary diseases. Methods: Serum CA19-9 levels were measured by radioimmunoassay in 514 patients (biliary diseases: 154, pancreatic diseases: 96, others: 264) who visited Asan Medical Center from February 1993 to February 1994. Results: The positive rates(>37U/ml) of CA19-9 were 67.3% and 47.9% in malignant and benign biliary diseases, 69.6% and 14.8% in malignant and benign pancreatic diseases, 21.3% and 20.0% in other malignant and benign diseases, respectively. The value of CA19-9 in benign biliary disease was significantly more elevated in the patients with cholangitis (median 65.5 U/ml) than patients without cholangitis (median 17.0 U/ml)(p0.01). In patients with benign and malignant biliary diseases, there was a positive correlation between CA19-9 and parameters representing biliary obstruction(alkaline phosphatase and bilirubin). In 7 patients with gallstone disease CA19-9 levels were significantly decreased after stone removal(p( 0.05). Follow-up levels of CA19-9 in 35 patients with biliary malignancy were also decreased after treatment(curative resection in 30 patients, chemotherapy in 2 patients, radiotherapy in 2 patients and management of cholangitis in 1 patient, respectively)(p(0.05). Sensitivity of CA19-9 at a cutoff value of 37 U/ml in pancreatic cancer was 69.6%, biliary malignancy 67.3%. Specificity in pancreatic cancer was 85.2%, biliary malignancy 52.1%. Positive predictive value in pancreatic cancer was 92.3%, biliary malignancy 65.3%. Conclusions: The measurement of CA19-9 can be used as an adjunctive test in the differential diagnosis of malignant and benign pancreaticobiliary diseases. On interpretation of an increased value of CA19-9 in these patients we should consider various conditions such as cholangitis or biliary obstruction with false positive value. (Korean J Gastroenterol 1995;27:347 - 355)
췌장 질환에 있어서 순수 췌액의 종양 표지자 측정에 관한 연구
김명환,이성구,서동완,최호순,유병무,김형건,민영일,이미화,유진숙 대한소화기내시경학회 1996 Clinical Endoscopy Vol.16 No.2
Several reports have described the usefulness of tumor markers detected in pancreatic juice for diagnosis of pancreatic cancer. We performed this study to evaluate the usefulness of tumor markers in pure pancreatic juice collected by duodenoscopic cannulation of pancreatic duct before and after injection of secretin. From April 1993 to July 1995, 8 cases of pancreatic cancer, 5 cases of benign pancreatic lesions, and 5 cases of benign biliary diseases without pancreatic lesion were involved. CEA and CA 19-9 immunoreactivity were measured by radioimmunoassay. Concentrations of CA 19-9 in pure pancreatic juice were significantly higher in patients with pancreatic cancer(median value; 3582, range 88.4-10410 IU/ml) than in control patients(median value 231, range 30.4-682 IU/ml)(p$lt;0.05). Concentrations of CEA in pure pancreatic juice were not significantly different between patients with pancreatic cancer(median value: 6,5, range 1.0-152ng/ml) and control patients(median value: 4.0, range 1-17.2 ng/ml)(p$gt;0.05). There was no significant correlation between levels of CA19-9, CEA in pancreatic juice and those levels in serum. The amounts of juice collected by duodenoscopic cannulation in patients with pancreatic cancer were 1.5+-0.9ml during 5 minutes before infusion of secretin, 11.3+-3.9ml, 10.8+-4.0ml, 10.6+-4.0ml in 5 minute interval after infusion of secretin. These results indicated that measurement of CA19-9 in pure pancreatic juice may be used as a marker for pancreatic cancer. Adequate amount of pancreatic juice was collected by duodenoscopic cannulation for evaluation of tumor marker, enzyme studies and cytology.